Search

Author/Creator Fabris, P.

1. Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network. Issue 1 (February 2018)

Authors:
Invernizzi, F.; Pasulo, L.; Aghemo, A.; Puoti, M.; Zaltron, S.; Maggiolo, F.; Rizzardini, G.; Fargion, S.; Sacchi, P.; Gulminetti, R.; Zuin, M.; Quirino, T.; Rumi, M.G.; Pan, A.; Grossi, P.; Rossini, A.; Corbellini, A.; Uberti Foppa, C.; Belli, L.; Piovesan, S.
Journal:
Digestive and liver disease
Issue:
Volume 50:Issue 1(2018)Supplement
Page Start:
32
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients. (February 2019)

Authors:
Gambato, M.; Spinetti, A.; Pasulo, L.; D'ambrosio, R.; Puoti, M.; Schiavini, M.; Fabris, P.; Sacchi, P.; Gulminetti, R.; Carolo, G.; Scotton, P.; Franceschet, I.; Vinci, M.; Viganò, M.; Lobello, S.; Zuin, M.G.; Aghemo, A.; Rumi, M.; Carrara, M.; Manfrin, V.
Journal:
Digestive and liver disease
Issue:
Volume 51(2019)Supplement 1
Page Start:
e55
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group. Issue 1 (February 2018)

Authors:
Degasperi, E.; Pasulo, L.; Aghemo, A.; Puoti, M.; Zaltron, S.; Maggiolo, F.; Rizzardini, G.; Fargion, S.; Sacchi, P.; Gulminetti, R.; Zuin, M.; Quirino, T.; Rumi, M.G.; Pan, A.; Grossi, P.; Rossini, A.; Corbellini, A.; Uberti Foppa, C.; Colli, A.; Piovesan, S.
Journal:
Digestive and liver disease
Issue:
Volume 50:Issue 1(2018)Supplement
Page Start:
52
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Impact of HBV infection in HCV/HBV coinfected patients treated with DAAs IN Northern Italy. (February 2020)

Authors:
Fabris, P.; Noventa, F.; Pasulo, L.; Farina, F.; Carollo, G.; Carlotto, A.; Rovere, P.; Cavinato, S.; Romano, A.; Vario, A.; Fraceschet, I.; Panese, S.; Bertin, T.; Zappalà, F.; Alberti, A.; Lobello, S.; Aghemo, A.; Bruno, R.; Puoti, M.; Rizzardini, G.
Journal:
Digestive and liver disease
Issue:
Volume 52(2020)Supplement 1
Page Start:
e19
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy. (February 2019)

Authors:
Pasulo, L.; Gambato, M.; Spinetti, A.; D'Ambrosio, R.; Puoti, M.; Ciancio, A.; Di Marco, V.; Calvaruso, V.; Colombatto, P.; Brunetto, M.; Schiavini, M.; Fabris, P.; Sacchi, P.; Gulminetti, R.; Carolo, G.; Scotton, P.; Pozzan, C.; Vinci, M.; Viganò, M.; Lombardi, A.
Journal:
Digestive and liver disease
Issue:
Volume 51(2019)Supplement 1
Page Start:
e16
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗